MM-302 monotherapy, in combination with trastuzumab, or trastuzumab plus cyclophosphamide, was well tolerated and showed promising efficacy. The selected phase 2 MM-302 dose was 30 mg/m² plus 6 mg/kg trastuzumab q3w.

2018年10月26日 · MM-302 is a HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate that targets HER2­overexpressing tumor cells, delivers doxorubicin to tumor cells, and limits exposure to...

2023年12月26日 · MM-302是一种新型抗HER2 ADC，由抗HER2 mAb与doxorubicin脂质体偶联[71]。 MM-302中的doxorubicin脂质体用于治疗BC和卵巢癌、骨髓瘤以及与艾滋病毒相关的卡波西肉瘤。

2019年10月1日 · MM-302 ADC ，将抗HER2单克隆抗体与脂质体doxorubicin偶联。 MM-302设计背后的目标是为了通过更好的靶向性，使用更高剂量的anthracycline。 早期临床前研究证明MM-302的活性优于anthracyclines 和 脂质体 doxorubicin。

2016年3月14日 · MM-302 is a HER2-targeted PEGylated liposome that encapsulates doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells while limiting exposure to nontarget tissues, including the heart. In this study, we evaluated the feasibility and preclinical activity of combining MM-302 with trastuzumab.

2016年6月3日 · MM-302 is a novel, HER2-targeted antibody-liposomal doxorubicin conjugate that specifically targets HER2-overexpressing cells. Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the ...

mm-302利用了细胞毒性化疗脂质体阿霉素，临床前研究表明其活性优于蒽环类药物和脂质体阿霉素，但在ii期试验中未达到终点。 Her2靶向ADC的连接子 为了成功地连接抗体和有效载荷，ADC的连接子构建必须满足一些关键标准。

Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells.

Upon administration of HER2-targeted liposomal doxorubicin hydrochloride MM-302, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the HER2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA ...

MM-302 is a HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate that targets HER2­overexpressing tumor cells, delivers doxorubicin to tumor cells, and limits exposure to healthy cells such as cardiomyocytes (Supplemental Fig. 1). 17,18 In preclinical models of HER2-positive breast cancer, MM-302 demonstrated superior antitumor ...